Clinical Trials Browser

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT06382948 2026-04-03

ADELA

Phase 3 Recruiting

240 enrolled

Breast

Advanced Breast Cancer

NCT06492616 2026-03-27

ELEGANT

Phase 3 Recruiting

4,220 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06923527 2026-03-27

Circulating Tumor DNA

Phase 2 Recruiting

50 enrolled

Breast

ER+ Breast Cancer

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

95 enrolled

Breast

Breast Neoplasms

NCT06075953 2026-03-16

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Phase 2 Recruiting

400 enrolled

Breast

Carcinoma, Intraductal, Noninfiltrating

NCT07222215 2026-01-22

CAPELA

Phase 2 Recruiting

297 enrolled

Breast

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast

Breast Neoplasms

NCT06691035 2025-12-04

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

Phase 1 Recruiting

18 enrolled

Breast

Breast Neoplasms

NCT06201234 2025-12-01

ELEMENT

Phase 2 Recruiting

176 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07159451 2025-12-01

POP-ELA

Phase 2 Recruiting

140 enrolled

Breast

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Phase 2 Recruiting

174 enrolled

Breast

Breast Neoplasms

NCT05512364 2025-08-19

TREAT ctDNA

Phase 3 Recruiting

220 enrolled

Breast

Breast Neoplasms

NCT06544577 2024-08-09

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

Recruiting

350 enrolled

Breast

ESR1 Gene Mutation